Cargando…

A Conformationally Constrained Cyclic Acyldepsipeptide Is Highly Effective in Mice Infected with Methicillin-Susceptible and -Resistant Staphylococcus aureus

BACKGROUND: Cyclic acyldepsipeptides (ADEPs) are a novel class of antibacterial agents, some of which (e.g., ADEP 4) are highly active against Gram-positive bacteria. The focus of these in vivo studies is ADEP B315, a rationally designed compound that has the most potent in vitro activity of any ADE...

Descripción completa

Detalles Bibliográficos
Autores principales: Arvanitis, Marios, Li, Gang, Li, De-Dong, Cotnoir, Daniel, Ganley-Leal, Lisa, Carney, Daniel W., Sello, Jason K., Mylonakis, Eleftherios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839560/
https://www.ncbi.nlm.nih.gov/pubmed/27101010
http://dx.doi.org/10.1371/journal.pone.0153912
_version_ 1782428138445209600
author Arvanitis, Marios
Li, Gang
Li, De-Dong
Cotnoir, Daniel
Ganley-Leal, Lisa
Carney, Daniel W.
Sello, Jason K.
Mylonakis, Eleftherios
author_facet Arvanitis, Marios
Li, Gang
Li, De-Dong
Cotnoir, Daniel
Ganley-Leal, Lisa
Carney, Daniel W.
Sello, Jason K.
Mylonakis, Eleftherios
author_sort Arvanitis, Marios
collection PubMed
description BACKGROUND: Cyclic acyldepsipeptides (ADEPs) are a novel class of antibacterial agents, some of which (e.g., ADEP 4) are highly active against Gram-positive bacteria. The focus of these in vivo studies is ADEP B315, a rationally designed compound that has the most potent in vitro activity of any ADEP analog reported to date. METHODS: In vivo efficacy experiments were performed using lethal intraperitoneal mice infection models with a methicillin-sensitive S. aureus (MSSA) and a methicillin-resistant (MRSA) strain. The infected mice were treated with ADEP B315, a des-methyl analog of ADEP 4, vancomycin, or the vehicle used for the ADEPs and their survival was assessed daily. A subset of MSSA-infected mice was sacrificed soon after inoculation and the bacterial burden was measured in their livers and spleens. The toxicity of ADEP B315 was assessed in viability assays using human whole blood cultures. RESULTS: In the MSSA experiments, all mice treated with the vehicle succumbed to the infection within 24 hours. All tested compounds were effective in prolonging survival of infected mice (p<0.001). Mice treated with ADEP B315 had a 39% survival rate by 10 days compared to 7% survival in mice treated with a des-methyl ADEP 4 analog (p = 0.017). Survival of the infected mice treated with ADEP B315 was comparable to those treated with vanocmycin (p = 0.12) at the same dose. Further, bacterial burden in the liver and spleen was significantly lower in mice treated with ADEP B315 compared to controls. In the MRSA experiments, ADEP B315 was able to significantly prolong survival compared to mice treated with either the vehicle (p = 0.001) or vancomycin (p = 0.007). ADEP B315 exhibited no significant toxicity in human whole blood cultures at concentrations up to 25 μg/ml. CONCLUSIONS: ADEP B315 is safe and can cure mice that have lethal infections of methicillin-sensitive and -resistant strains of S. aureus.
format Online
Article
Text
id pubmed-4839560
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48395602016-04-29 A Conformationally Constrained Cyclic Acyldepsipeptide Is Highly Effective in Mice Infected with Methicillin-Susceptible and -Resistant Staphylococcus aureus Arvanitis, Marios Li, Gang Li, De-Dong Cotnoir, Daniel Ganley-Leal, Lisa Carney, Daniel W. Sello, Jason K. Mylonakis, Eleftherios PLoS One Research Article BACKGROUND: Cyclic acyldepsipeptides (ADEPs) are a novel class of antibacterial agents, some of which (e.g., ADEP 4) are highly active against Gram-positive bacteria. The focus of these in vivo studies is ADEP B315, a rationally designed compound that has the most potent in vitro activity of any ADEP analog reported to date. METHODS: In vivo efficacy experiments were performed using lethal intraperitoneal mice infection models with a methicillin-sensitive S. aureus (MSSA) and a methicillin-resistant (MRSA) strain. The infected mice were treated with ADEP B315, a des-methyl analog of ADEP 4, vancomycin, or the vehicle used for the ADEPs and their survival was assessed daily. A subset of MSSA-infected mice was sacrificed soon after inoculation and the bacterial burden was measured in their livers and spleens. The toxicity of ADEP B315 was assessed in viability assays using human whole blood cultures. RESULTS: In the MSSA experiments, all mice treated with the vehicle succumbed to the infection within 24 hours. All tested compounds were effective in prolonging survival of infected mice (p<0.001). Mice treated with ADEP B315 had a 39% survival rate by 10 days compared to 7% survival in mice treated with a des-methyl ADEP 4 analog (p = 0.017). Survival of the infected mice treated with ADEP B315 was comparable to those treated with vanocmycin (p = 0.12) at the same dose. Further, bacterial burden in the liver and spleen was significantly lower in mice treated with ADEP B315 compared to controls. In the MRSA experiments, ADEP B315 was able to significantly prolong survival compared to mice treated with either the vehicle (p = 0.001) or vancomycin (p = 0.007). ADEP B315 exhibited no significant toxicity in human whole blood cultures at concentrations up to 25 μg/ml. CONCLUSIONS: ADEP B315 is safe and can cure mice that have lethal infections of methicillin-sensitive and -resistant strains of S. aureus. Public Library of Science 2016-04-21 /pmc/articles/PMC4839560/ /pubmed/27101010 http://dx.doi.org/10.1371/journal.pone.0153912 Text en © 2016 Arvanitis et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Arvanitis, Marios
Li, Gang
Li, De-Dong
Cotnoir, Daniel
Ganley-Leal, Lisa
Carney, Daniel W.
Sello, Jason K.
Mylonakis, Eleftherios
A Conformationally Constrained Cyclic Acyldepsipeptide Is Highly Effective in Mice Infected with Methicillin-Susceptible and -Resistant Staphylococcus aureus
title A Conformationally Constrained Cyclic Acyldepsipeptide Is Highly Effective in Mice Infected with Methicillin-Susceptible and -Resistant Staphylococcus aureus
title_full A Conformationally Constrained Cyclic Acyldepsipeptide Is Highly Effective in Mice Infected with Methicillin-Susceptible and -Resistant Staphylococcus aureus
title_fullStr A Conformationally Constrained Cyclic Acyldepsipeptide Is Highly Effective in Mice Infected with Methicillin-Susceptible and -Resistant Staphylococcus aureus
title_full_unstemmed A Conformationally Constrained Cyclic Acyldepsipeptide Is Highly Effective in Mice Infected with Methicillin-Susceptible and -Resistant Staphylococcus aureus
title_short A Conformationally Constrained Cyclic Acyldepsipeptide Is Highly Effective in Mice Infected with Methicillin-Susceptible and -Resistant Staphylococcus aureus
title_sort conformationally constrained cyclic acyldepsipeptide is highly effective in mice infected with methicillin-susceptible and -resistant staphylococcus aureus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839560/
https://www.ncbi.nlm.nih.gov/pubmed/27101010
http://dx.doi.org/10.1371/journal.pone.0153912
work_keys_str_mv AT arvanitismarios aconformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT ligang aconformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT lidedong aconformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT cotnoirdaniel aconformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT ganleyleallisa aconformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT carneydanielw aconformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT sellojasonk aconformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT mylonakiseleftherios aconformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT arvanitismarios conformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT ligang conformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT lidedong conformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT cotnoirdaniel conformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT ganleyleallisa conformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT carneydanielw conformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT sellojasonk conformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus
AT mylonakiseleftherios conformationallyconstrainedcyclicacyldepsipeptideishighlyeffectiveinmiceinfectedwithmethicillinsusceptibleandresistantstaphylococcusaureus